Login / Signup

Targeting pteridine reductase 1 and dihydrofolate reductase: the old is a new trend for leishmaniasis drug discovery.

Gustavo Machado das NevesLuciano P KagamiItamar L GonçalvesVera L Eifler-Lima
Published in: Future medicinal chemistry (2019)
Leishmaniasis is one of the major neglected tropical diseases in the world and it is considered endemic in 88 countries. This disease is transmitted by a Leishmania spp. infected sandfly and it may lead to cutaneous or systemic manifestations. The preconized treatment has low efficacy and there are cases of resistance to some drugs. Therefore, the search for new efficient molecular targets that can lead to the preparation of new drugs must be pursued. This review aims to evaluate both Leishmania enzymes PTR1 and DHFR-TS as potential drug targets, highlight their inhibitors and to discuss critically the use of chemoinformatics to elucidate interactions and propose new molecules against these enzymes.
Keyphrases
  • drug discovery
  • drug induced
  • emergency department
  • cancer therapy
  • combination therapy
  • risk assessment
  • molecularly imprinted
  • mass spectrometry